

**Sup. Table S1**

<b>Tukey's multiple comparisons test</b>	<b>Mean Diff.</b>	<b>95% CI of diff.</b>	<b>Significant</b>	<b>Summary</b>	<b>Adjusted P Value</b>
<b>CHO</b>					
Control vs. HO-3867	-0.1333	-3.567 to 3.300	No	ns	0.9948
Control vs. H-4073	-13.14	-16.57 to -9.706	Yes	****	< 0.0001
HO-3867 vs. H-4073	-13.01	-16.44 to -9.573	Yes	****	< 0.0001
<b>H9C2</b>					
Control vs. HO-3867	3.537	0.1029 to 6.970	Yes	*	0.0426
Control vs. H-4073	-10.35	-13.79 to -6.920	Yes	****	< 0.0001
HO-3867 vs. H-4073	-13.89	-17.32 to -10.46	Yes	****	< 0.0001
<b>A2780</b>					
Control vs. HO-3867	-54.06	-57.49 to -50.62	Yes	****	< 0.0001
Control vs. H-4073	-67.82	-71.25 to -64.38	Yes	****	< 0.0001
HO-3867 vs. H-4073	-13.76	-17.19 to -10.33	Yes	****	< 0.0001

Table 1: Results of Tukey's post-hoc test using a 95% confidence interval ( $\alpha = 0.05$ ) for analysis of apoptosis data. The data was grouped according to cell type, and comparisons between different cell types were not considered.

**Sup. Table S2**

<b>DAP - compounds</b>	<b>Base Molecular Weight</b>	<b>Major Metabolic Product Weight</b>	<b>Metabolic Product Classification</b>
<b>HO-3867</b>	465.12	469.87	<i>M+4</i>
<b>H-4073</b>	312.10	316.57	<i>M+4</i>

Table 2. Molecular weights of the pure DAP compounds and the primary metabolic product from *in vitro* studies as determined by LCMS analysis.